Testing petrelintide for weight loss in people with type 2 diabetes
Compares a new weekly medicine with placebo in adults with excess weight and diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Key facts
- Where
- Bialystok, Cracow, Mazowieckie, and Warsaw, PolandSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity and type 2 diabetes. It compares weekly petrelintide with placebo for weight management, together with a reduced-calorie diet and more physical activity.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- BMI of 27 kg/m² or more. Type 2 diabetes with HbA1c from 6.5% (48 mmol/mol) to 10% (48-86 mmol/mol), measured at screening.
- Earlier treatment
- Stable treatment for at least 90 days before and during screening: diet and exercise alone, basal insulin, or selected oral glucose-lowering medicines. At least one self-reported unsuccessful diet effort to lose weight.
- Biomarker or test result
- HbA1c from 6.5% (48 mmol/mol) to 10% (48-86 mmol/mol), measured by the central laboratory at screening.
Main reasons for not taking part
- Current or past proliferative diabetic retinopathy or diabetic macular edema
- Current or past treatment with petrelintide or any other amylin analog
Read by machine on 12 November 2026.
Where in Poland
- NZOZ Vita-Diabetica Malgorzata BuraczykBialystok, PolandNot yet recruiting
- Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.Cracow, PolandNot yet recruiting
- Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met Sp. z o.o.Cracow, PolandNot yet recruiting
- NBR PolskaMazowieckie, PolandNot yet recruiting
- Etg Warszawa Sp. z o.o.Warsaw, PolandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07843485EU 2026-526189-25-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).Read full original descriptionShow less
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Inclusion: Participants with BMI ≥ 27 kg/m²; T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening; Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Current or previous treatment with petrelintide or any other amylin analog; History or presence of proliferative diabetic retinopathy, or diabetic macular edema.